{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:47:16Z","timestamp":1786996036829,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.psc.2022.05.004","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T07:40:48Z","timestamp":1659339648000},"page":"431-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Important Drug-Drug Interactions for the Addiction Psychiatrist"],"prefix":"10.1016","volume":"45","author":[{"given":"Neil","family":"Sandson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psc.2022.05.004_bib1","series-title":"Cogentin package insert","year":"1996"},{"key":"10.1016\/j.psc.2022.05.004_bib2","series-title":"Nardil package insert","year":"2003"},{"key":"10.1016\/j.psc.2022.05.004_bib3","series-title":"Parnate package insert","year":"2001"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STAR\u2217D): rationale and design","volume":"25","author":"Rush","year":"2004","journal-title":"Control Clin Trials"},{"issue":"4","key":"10.1016\/j.psc.2022.05.004_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-0773.1996.tb00215.x","article-title":"Interaction of mu-opioid antagonistic drugs with antiepileptics","volume":"78","author":"Frey","year":"1996","journal-title":"Pharmacol Toxicol"},{"issue":"1\u20133","key":"10.1016\/j.psc.2022.05.004_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0009-2797(00)00225-8","article-title":"In\u00a0vivo inhibition of aldehyde dehydrogenase by disulfiram","volume":"130-132","author":"Lipsky","year":"2001","journal-title":"Chem Biol Interact"},{"issue":"6","key":"10.1016\/j.psc.2022.05.004_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003088-199936060-00004","article-title":"Drug interactions with tobacco smoking. an update","volume":"36","author":"Zevin","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.psc.2022.05.004_bib8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/neu.10148","article-title":"Cellular and synaptic mechanisms of nicotine addiction","volume":"53","author":"Mansvelder","year":"2002","journal-title":"J\u00a0Neurobiol"},{"issue":"6","key":"10.1016\/j.psc.2022.05.004_bib9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF00053022","article-title":"Nicotine and sympathetic neurotransmission","volume":"10","author":"Haass","year":"1997","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"10.1016\/j.psc.2022.05.004_bib10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.freeradbiomed.2007.11.004","article-title":"CYP2E1 and oxidative liver injury by alcohol","volume":"44","author":"Lu","year":"2008","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"10.1016\/j.psc.2022.05.004_bib11","first-page":"245","article-title":"Overview: how is alcohol metabolized by the body?","volume":"29","author":"Zakhari","year":"2006","journal-title":"Alcohol Res Health"},{"issue":"6","key":"10.1016\/j.psc.2022.05.004_bib12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/cpt.1083","article-title":"Drinking ethanol has few acute effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein activities but somewhat inhibits CYP1A2, CYP2D6, and intestinal CYP3A: so what?","volume":"104","author":"Gazzaz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.psc.2022.05.004_bib13","first-page":"826","article-title":"Inhibition of caffeine elimination by short-term ethanol administration","volume":"101","author":"Mitchell","year":"1983","journal-title":"J\u00a0Lab Clin Med"},{"issue":"3","key":"10.1016\/j.psc.2022.05.004_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1067\/mcp.2000.104736","article-title":"Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation","volume":"67","author":"Manyike","year":"2000","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.psc.2022.05.004_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1067\/mcp.2000.106574","article-title":"Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults","volume":"67","author":"Thummel","year":"2000","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.15344\/2456-8007\/2019\/132","article-title":"Marijuana and cardiac arrhythmias: a scoping study","volume":"4","author":"Kariyanna","year":"2019","journal-title":"Int J Clin Res Trials"},{"issue":"4","key":"10.1016\/j.psc.2022.05.004_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0301-0082(98)00087-2","article-title":"The effects of cannabinoids on the brain","volume":"58","author":"Ameri","year":"1999","journal-title":"Prog Neurobiol"},{"issue":"5","key":"10.1016\/j.psc.2022.05.004_bib18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2174\/1871527316666170413104516","article-title":"Neuropsychiatric and general interactions of natural and synthetic cannabinoids with drugs of abuse and medicines","volume":"16","author":"Arellano","year":"2017","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"6","key":"10.1016\/j.psc.2022.05.004_bib19","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0006-2952(93)90286-6","article-title":"Characterization of cannabidiol-mediated cytochrome P450 inactivation","volume":"45","author":"Bornheim","year":"1993","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.psc.2022.05.004_bib20","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/JCP.0000000000001089","article-title":"The potential for pharmacokinetic interactions between cannabis products and conventional medications","volume":"39","author":"Qian","year":"2019","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib21","first-page":"3","article-title":"Medicinal cannabis-potential drug interactions","volume":"6","author":"Alsherbiny","year":"2018","journal-title":"Medicines (Basel)"},{"key":"10.1016\/j.psc.2022.05.004_bib22","doi-asserted-by":"crossref","first-page":"3902740","DOI":"10.1155\/2020\/3902740","article-title":"Potential pharmacokinetic drug-drug interactions between cannabinoids and drugs used for chronic pain","volume":"2020","author":"V\u00e1zquez","year":"2020","journal-title":"Biomed Res Int"},{"issue":"7","key":"10.1016\/j.psc.2022.05.004_bib23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1017\/S1461145709990848","article-title":"Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)","volume":"13","author":"Tournier","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib24","first-page":"35","article-title":"Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors","volume":"270","author":"Pellinen","year":"1994","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.psc.2022.05.004_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4155\/fmc.11.181","article-title":"Accelerating cocaine metabolism as an approach to the treatment of cocaine abuse and toxicity","volume":"4","author":"Schindler","year":"2012","journal-title":"Future Med Chem"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/1874473710666170920143344","article-title":"Drug-drug interactions in cocaine-users and their clinical implications","volume":"10","author":"Gallelli","year":"2017","journal-title":"Curr Drug Abuse Rev"},{"issue":"8","key":"10.1016\/j.psc.2022.05.004_bib27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/jat\/30.8.501","article-title":"Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration","volume":"30","author":"Kolbrich","year":"2006","journal-title":"J\u00a0Anal Toxicol"},{"issue":"5","key":"10.1016\/j.psc.2022.05.004_bib28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000139058","article-title":"Norcocaine and N-hydroxynorcocaine formation in human liver microsomes: role of cytochrome P-450 3A4","volume":"46","author":"LeDuc","year":"1993","journal-title":"Pharmacology"},{"issue":"8","key":"10.1016\/j.psc.2022.05.004_bib29","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1124\/dmd.107.015354","article-title":"Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17","volume":"35","author":"Shen","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.psc.2022.05.004_bib30","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0006-2952(02)01028-6","article-title":"Reduced (+\/-)-3,4-methylenedioxymethamphetamine (\"Ecstasy\") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in\u00a0vitro","volume":"63","author":"Ramamoorthy","year":"2002","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0026-895X(25)12855-1","article-title":"Neuronal cytochrome P450IID1 (debrisoquine\/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6","volume":"40","author":"Tyndale","year":"1991","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0006-291X(88)80729-0","article-title":"Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl\/bufI)","volume":"152","author":"Dayer","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"issue":"27","key":"10.1016\/j.psc.2022.05.004_bib33","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1056\/NEJMoa041888","article-title":"Codeine intoxication associated with ultrarapid CYP2D6 metabolism","volume":"351","author":"Gasche","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.psc.2022.05.004_bib34","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/jcph.469","article-title":"Pharmacokinetic interaction of intravenous fentanyl with ketoconazole","volume":"55","author":"Ziesenitz","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.psc.2022.05.004_bib35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/00000542-200204000-00019","article-title":"Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein","volume":"96","author":"Wandel","year":"2002","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.psc.2022.05.004_bib36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0022-3565(25)21180-6","article-title":"Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases","volume":"279","author":"Kamendulis","year":"1996","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.psc.2022.05.004_bib37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/clpt.1993.177","article-title":"CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone","volume":"54","author":"Otton","year":"1993","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.psc.2022.05.004_bib38","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/jcph.1873","article-title":"Pharmacogenomics and Morphine","volume":"61","author":"Ofoegbu","year":"2021","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.psc.2022.05.004_bib39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40265-013-0036-0","article-title":"Cytochrome P450-mediated changes in oxycodone pharmacokinetics\/pharmacodynamics and their clinical implications","volume":"73","author":"S\u00f6derberg-L\u00f6fdal","year":"2013","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.psc.2022.05.004_bib41","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3109\/00498259609050260","article-title":"Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily","volume":"26","author":"Ono","year":"1996","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.psc.2022.05.004_bib42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1208\/s12248-020-00513-5","article-title":"Construction and verification of physiologically based pharmacokinetic models for four drugs majorly cleared by glucuronidation: lorazepam, oxazepam, naloxone, and zidovudine","volume":"22","author":"Docci","year":"2020","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib43","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FTD.0b013e318030def0","article-title":"Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese","volume":"29","author":"Goto","year":"2007","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/1573397111666151026223914","article-title":"Clinical pharmacology of phenobarbital in neonates: effects, metabolism and pharmacokinetics","volume":"12","author":"Pacifici","year":"2016","journal-title":"Curr Pediatr Rev"},{"issue":"2","key":"10.1016\/j.psc.2022.05.004_bib45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.seizure.2007.11.012","article-title":"Pharmacokinetic interactions between contraceptives and antiepileptic drugs","volume":"17","author":"Sabers","year":"2008","journal-title":"Seizure"},{"issue":"11","key":"10.1016\/j.psc.2022.05.004_bib46","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: an update","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch Toxicol"},{"issue":"6","key":"10.1016\/j.psc.2022.05.004_bib47","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","article-title":"Methadone--metabolism, pharmacokinetics and interactions","volume":"50","author":"Ferrari","year":"2004","journal-title":"Pharmacol Res"},{"issue":"9","key":"10.1016\/j.psc.2022.05.004_bib48","first-page":"1059","article-title":"Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6","volume":"25","author":"Lin","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.psc.2022.05.004_bib49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fgene.2012.00235","article-title":"MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?","volume":"3","author":"de la Torre","year":"2012","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/135965350000500108","article-title":"Possible fatal interaction between protease inhibitors and methamphetamine","volume":"5","author":"Hales","year":"2000","journal-title":"Antivir Ther"},{"issue":"2","key":"10.1016\/j.psc.2022.05.004_bib51","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0006-8993(97)00754-3","article-title":"Differential toxic effects of methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) in multidrug-resistant (mdr1a) knockout mice","volume":"769","author":"Mann","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.psc.2022.05.004_bib52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/978-3-540-74806-9_15","article-title":"Ketamine","volume":"182","author":"Sinner","year":"2008","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib53","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/20961790.2017.1285219","article-title":"Metabolism and metabolomics of ketamine: a toxicological approach","volume":"2","author":"Dinis-Oliveira","year":"2017","journal-title":"Forensic Sci Res"},{"issue":"7","key":"10.1016\/j.psc.2022.05.004_bib54","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/dmd.30.7.853","article-title":"Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes","volume":"30","author":"Hijazi","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.psc.2022.05.004_bib55","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/clpt.2011.140","article-title":"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine","volume":"90","author":"Peltoniemi","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.psc.2022.05.004_bib56","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1124\/dmd.117.078360","article-title":"Ketamine pharmacokinetics and pharmacodynamics are altered by p-glycoprotein and breast cancer resistance protein efflux transporters in mice","volume":"46","author":"Ganguly","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.psc.2022.05.004_bib57","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib58","first-page":"9","article-title":"Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug","volume":"8","author":"Bey","year":"2007","journal-title":"Cal J Emerg Med"},{"issue":"5","key":"10.1016\/j.psc.2022.05.004_bib59","first-page":"557","article-title":"Metabolism of phencyclidine by human liver microsomes","volume":"25","author":"Laurenzana","year":"1997","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.psc.2022.05.004_bib60","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0006-2952(84)90314-9","article-title":"Induction of phencyclidine metabolism by phencyclidine, ketamine, ethanol, phenobarbital and isosafrole","volume":"33","author":"Kammerer","year":"1984","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.psc.2022.05.004_bib61","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1124\/dmd.108.024661","article-title":"Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling","volume":"37","author":"Shebley","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.psc.2022.05.004_bib62","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcp.12070","article-title":"The clinical pharmacology of acamprosate","volume":"77","author":"Kalk","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.psc.2022.05.004_bib63","first-page":"313","article-title":"Buprenorphine therapy for opioid use disorder","volume":"97","author":"Zoorob","year":"2018","journal-title":"Am Fam Physician"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1124\/dmd.109.029546","article-title":"Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes","volume":"38","author":"Rouguieg","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.psc.2022.05.004_bib65","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0090-9556(24)15310-X","article-title":"Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1","volume":"27","author":"Kharasch","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.psc.2022.05.004_bib66","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1021\/mp049917l","article-title":"Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein","volume":"1","author":"Loo","year":"2004","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.psc.2022.05.004_bib67","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/ALN.0000000000000867","article-title":"Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism","volume":"123","author":"Kharasch","year":"2015","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.psc.2022.05.004_bib68","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cpdd.326","article-title":"Current concepts in methadone metabolism and transport","volume":"6","author":"Kharasch","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"10.1016\/j.psc.2022.05.004_bib69","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1365-2125.2011.04145.x","article-title":"Methadone inhibits CYP2D6 and UGT2B7\/2B4 in\u00a0vivo: a study using codeine in methadone- and buprenorphine-maintained subjects","volume":"73","author":"Gelston","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.psc.2022.05.004_bib70","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/jat\/bku019","article-title":"Naltrexone metabolism and concomitant drug concentrations in chronic pain patients","volume":"38","author":"Liu","year":"2014","journal-title":"J\u00a0Anal Toxicol"},{"issue":"1","key":"10.1016\/j.psc.2022.05.004_bib71","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1124\/dmd.105.006767","article-title":"Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in\u00a0vivo and in\u00a0vitro","volume":"34","author":"Obach","year":"2006","journal-title":"Drug Metab Dispos"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X22000466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X22000466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T01:42:13Z","timestamp":1759282933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X22000466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0193953X22000466"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2022.05.004","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Important Drug-Drug Interactions for the Addiction Psychiatrist","name":"articletitle","label":"Article Title"},{"value":"Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psc.2022.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}